Slow-degrading polymers comprising salicylic acid for undelayed and sustained drug delivery

• US 8,741,317 B2
• Filed: 08/19/2011
• Issued: 06/03/2014
• Est. Priority Date: 08/19/2010
• Status: Active Grant

• Current Assignee: Rutgers University
• Original Assignee: Rutgers University
• Inventors: Uhrich, Kathryn E., Rosario-Melndez, Roselin
• Primary Examiner(s): Sims, Jason
• Assistant Examiner(s): Levin, Miriam A
• Application Number:
  US13/213,843
• Publication Number:
  US 20120058155A1
• Time in Patent Office: 1,019 Days
• Field of Search: 424/400, 424/78.37, 428/402, 528/194
• US Class Current: 424/400
• CPC Class Codes: A61K 31/185 Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids hydroxamic acids A61K31/16; peroxy acids A61K31/327
• CPC Class Codes: A61K 31/775 Phenolic resins
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: C08G 67/04 Polyanhydrides
• CPC Class Codes: Y10T 428/2982 Particulate matter [e.g., sphere, flake, etc.]

Abstract

The invention provides polymers and methods for their use. Specifically, certain embodiments of the present invention provide a polymer that comprises a plurality of salicylic acid-adipic (SA-Adipic) units of the following formula

and a plurality of salicylic acid-diethylmalonic (SA-DEM) units of the following formula

Certain embodiments of the invention also provide slow degrading microspheres comprising polymers described herein for undelayed and sustained drug delivery. Certain embodiments of the present invention provide methods for treating a chronic eye disease or arthritis in a patient, comprising administering to the patient a therapeutically effective amount of a polymer or microsphere as described herein.

Claims

1. A polymer that comprises a plurality of salicylic acid-adipic (SA-Adipic) units of the following formula

2. The polymer of claim 1 that has an average molecular weight of about 20,000 daltons to about 50,000 daltons.

3. The polymer of claim 1 that has an average molecular weight of about 10,000 daltons to about 25,000 daltons.

4. The polymer of claim 1, wherein the ratio of SA-Adipic units to SA-DEM units in the polymer is about 50:

50.

5. The polymer of claim 1, wherein the ratio of SA-Adipic units to SA-DEM units in the polymer is about 75:

25.

6. A pharmaceutical composition comprising a polymer as described in claim 1 and a pharmaceutically acceptable carrier.

7. A method for delivering salicylic acid to a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a polymer as described in claim 1.

8. A method for treating a chronic eye disease in a patient, comprising administering to the patient a therapeutically effective amount of a polymer as described in claim 1.

9. A method for treating arthritis in a patient, comprising administering to the patient a therapeutically effective amount of a polymer as described in claim 1.

10. A microsphere comprising the polymer of claim 1.

11. The microsphere of claim 10, wherein the polymer has an average molecular weight of about 20,000 daltons to about 50,000 daltons.

12. The microsphere of claim 10, wherein the polymer has an average molecular weight of about 10,000 daltons to about 25,000 daltons.

13. The microsphere of claim 10, wherein the ratio of SA-Adipic units to SA-DEM units in the polymer is about 50:

50.

14. The microsphere of claim 10, wherein the ratio of SA-Adipic units to SA-DEM units in the polymer is about 75:

25.

15. The microsphere of claim 10, wherein the diameter of the microsphere is between about 10 μ

m to about 30 μ

m.

16. A pharmaceutical composition comprising a microsphere as described in claim 10 and a pharmaceutically acceptable carrier.

17. A method for delivering salicylic acid to a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a microsphere as described in claim 10.

18. A method for treating a chronic eye disease in a patient, comprising administering to the patient a therapeutically effective amount of a microsphere as described in claim 10.

19. A method for treating arthritis in a patient, comprising administering to the patient a therapeutically effective amount of a microsphere as described in claim 10.

20. The polymer of claim 1, wherein the ratio of SA-Adipic units to SA-DEM units in the polymer is about 25:

75.

21. The microsphere of claim 10, wherein the ratio of SA-Adipic units to SA-DEM units in the polymer is about 25:

75.